Abstract
Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment landscape of lymphoid malignancies. Six CAR T-cell products have been approved by the US Food and Drug Administration since 2017.1–5 A single dose of autologous CD19-directed CAR T-cells showed objective response rates of 64–95% for patients with relapsed or refractory B-cell malignancies, with a subset of responding patients having durable remission.1–3 Similarly, B-cell maturation antigen (BCMA) targeting CAR T-cells have yielded promising efficacy in relapsed and refractory multiple myeloma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
